Storia in 2 fonti

The GLP-1 paradox: too expensive to cover, too effective to cut | Fortune

A founder and a former HHS CTO agree: GLPs are breaking the healthcare system. We need to move away from drug-first or diet-first obesity care.

Raccontata da

fortune.com

hbr.org

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fortune.comStai leggendo1 g fa

The GLP-1 paradox: too expensive to cover, too effective to cut | Fortune

A founder and a former HHS CTO agree: GLPs are breaking the healthcare system. We need to move away from drug-first or diet-first obesity care.

originale

hbr.org14 h fa

GLP-1s and the High Cost of Providing Health Care

Rising demand for GLP-1 drugs like Ozempic and Wegovy is forcing companies to decide whether to cover, limit, or drop the benefit, with the medications costing employers up to $7,000 per employee annually. Prices are…

Leggi questa versione → originale

Timeline cronologica

giovedì 23 luglio 2026·fortune.com
The GLP-1 paradox: too expensive to cover, too effective to cut | Fortune
A founder and a former HHS CTO agree: GLPs are breaking the healthcare system. We need to move away from drug-first or diet-first obesity care.
venerdì 24 luglio 2026·hbr.org
GLP-1s and the High Cost of Providing Health Care
Rising demand for GLP-1 drugs like Ozempic and Wegovy is forcing companies to decide whether to cover, limit, or drop the benefit, with the medications costing employers up to…